New study shows the presence of universally effective antibodies in new coronary patients

There is no “magic cure” for the new coronavirus, but scientists have found more evidence that the human immune system can develop neutralizing antibodies that can block viral infections in cells. These antibodies can be used to develop treatments for COVID-19, including vaccines and monoclonal antibodies, which act like resusive plasma therapy. These “god drugs” are “trained” by the immune system to produce antibodies to any pathogen entering the body. Immune cells recognize foreign cells, label them, and destroy them. The resulting antibodies prevent the same infectious microorganisms from reinfecting human cells, which is why plasma therapy works.

Now, researchers from Rockefeller University have published a study detailing the presence of generally effective antibodies.

New study shows the presence of universally effective antibodies in new coronary patients

The researchers looked at 149 patients recovering from COVID-19 and found that not all of them produced the same type of immune response. Some people don’t even have the kind of strong neutralizing antibodies that suppress the virus, but they produce other types of antibodies. The good news is that many people produce strong neutralizing antibodies that bind to the S protein of COVID-19, an ingredient that allows the virus to enter human cells and replicate.

Patients showed symptoms on average within 12 days and were collected about 39 days after the onset of symptoms. The scientists then wrote a paper that included testing the collected plasma for the pseudo-SARS-CoV-2 virus and measuring the effectiveness of the antibodies. In 33% of cases, the level of medhesis was below the detectable level. This may mean that the patient has recovered from the infection before producing stronger antibodies. This also means that the plasma obtained from these donors will not be as effective for some patients as others.

Most of the samples showed “moderate neutrality and activity,’ indicating a weaker antibody response, the researchers said. Even so, these patients were able to survive and improve after COVID-19 infection. “A closer look reveals that everyone’s immune system produces effective antibodies — just not necessarily enough antibodies,” the researchers explained in a statement.

“It shows that almost everyone can do this, which is very good news for vaccines,” said Michel C. Nussenzweig, director of the Rockefeller Molecular Immunology Laboratory. “This means that if you can make a vaccine that induces these special antibodies, it’s probably effective, and it works for a lot of people.” “

About 1% of donors have amazing neutralizing antibodies. The team identified 40 antibodies that neutralise the virus, including three unique antibodies that bind to the S protein, which can be further developed into therapeutic and preventive drugs. Even low-dose antibodies are very effective, and the same antibodies have been found in more than one donor.

“We now know what an effective antibody looks like, and we found similar antibodies in more than one person,” said researcher Davide F. Robbiani. “This is important information for those who are designing and testing vaccines. If they see that their vaccine can cause these antibodies, they know they are heading in the right direction. “

The study was published in the form of an unreviewed version of bioRxiv, but was consistent with similar work by other scientists. While some people are working on vaccines that can prevent SARS-CoV-2 infection, several companies are testing monoclonal antibody drugs that can be used to treat COVID-19 patients and eliminate the virus. Such drugs can also provide people with temporary immunity, as long as the antibodies circulate in the blood, because antibodies effectively “patrol” the body to find the virus, can provide people with temporary immunity.